Lung Cancer Clinical Trials

• Voluntarily sign the informed consent form and comply with the protocol requirements;

• No gender restrictions;

• Age: ≥18 years and ≤75 years (Phase Ia); ≥18 years (Phase Ib);

• Expected survival time ≥3 months;

• Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer or other solid tumors that have failed standard treatment;

• Willing to provide archived or fresh tumor tissue samples from primary or metastatic lesions within the past 2 years;

• Must have at least one measurable lesion as defined by RECIST v1.1;

• ECOG performance status score of 0 or 1;

• Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;

⁃ No severe cardiac dysfunction, left ventricular ejection fraction (LVEF) ≥50%;

⁃ Organ function levels must meet the requirements;

⁃ Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × upper limit of normal (ULN);

⁃ Urine protein ≤2+ or ≤1000mg/24h;

⁃ For premenopausal women with childbearing potential, a serum pregnancy test must be negative within 7 days before starting treatment, and they must not be breastfeeding. All enrolled patients (regardless of gender) must use adequate barrier contraception throughout the treatment period and for 6 months after treatment completion;

⁃ The subject has the ability and willingness to comply with the visits, treatment plans, laboratory tests, and other study-related procedures specified in the protocol.